Low level natural antibodies against phosphorylcholine: A novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease

Clinical Immunology

Volumn 134, Issue 1, 2010, Pages 47-54

  Frostegård, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Inflammation; Innate immunity; Phospholipids

Indexed keywords

ANTIBODY; ANTIINFLAMMATORY AGENT; CHOLINE DERIVATIVE; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; PHOSPHORYLCHOLINE; PHOSPHORYLCHOLINE ANTIBODY; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIAGNOSTIC PROCEDURE; DIET; DISEASE COURSE; HEART INFARCTION; HUMAN; NONHUMAN; PAPUA NEW GUINEA; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ATHEROSCLEROSIS; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, LDL; MODELS, IMMUNOLOGICAL; OXIDATION-REDUCTION; PHOSPHORYLCHOLINE; RISK FACTORS;

EID: 71649096567     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.08.013     Document Type: Review

References (89)

1. Mayerl C., Lukasser M., Sedivy R., Niederegger H., Seiler R., and Wick G. Atherosclerosis research from past to present-on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch. 449 1 (2006) 96-103
2. Jonasson L., Holm J., Skalli O., Bondjers G., and Hansson G.K. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6 2 (1986) 131-138
3. Lindeberg S., and Lundh B. Apparent absence of stroke and ischaemic heart disease in a traditional Melanesian island: a clinical study in Kitava. J. Intern. Med. 233 3 (1993) 269-275
4. Sunnemark D., Harris R.A., Frostegard J., and Orn A. Induction of early atherosclerosis in CBA/J mice by combination of Trypanosoma cruzi infection and a high cholesterol diet. Atherosclerosis 153 2 (2000) 273-282
5. George J., Harats D., Gilburd B., Afek A., Shaish A., Kopolovic J., and Shoenfeld Y. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102 15 (2000) 1822-1827
6. George J., Afek A., Gilburd B., Harats D., and Shoenfeld Y. Autoimmunity in atherosclerosis: lessons from experimental models. Lupus 9 3 (2000) 223-227
7. 1) and macrophage-stimulating cytokines. Atherosclerosis 145 1 (1999) 33-43
8. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 9 (2002) 1135-1143
9. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of infammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 (2000) 836-843
10. Packard R.R., and Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 54 1 (2008) 24-38
11. Dollery C.M., and Libby P. Atherosclerosis and proteinase activation. Cardiovasc. Res. 69 3 (2006) 625-635
12. Funk C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat. Rev., Drug Discov. 4 8 (2005) 664-672
13. 4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. U. S. A. 103 21 (2006) 8161-8166
14. Xu Q., Dietrich H., Steiner H.J., Gown A.M., Schoel B., Mikuz G., Kaufmann S.H., and Wick G. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. 12 7 (1992) 789-799
15. Frostegard J., Lemne C., Andersson B., van der Zee R., Kiessling R., and de Faire U. Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension 29 1 Pt 1 (1997) 40-44
16. Pockley A.G., Wu R., Lemne C., Kiessling R., de Faire U., and Frostegard J. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension 36 2 (2000) 303-307
17. Frostegard J., Kjellman B., Gidlund M., Andersson B., Jindal S., and Kiessling R. Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis 121 1 (1996) 93-103
18. Ross R. The pathogenesis of atherosclerosis-an update. N. Engl. J. Med. 314 8 (1986) 488-500
19. Binder C.J., Chang M.K., Shaw P.X., Miller Y.I., Hartvigsen K., Dewan A., and Witztum J.L. Innate and acquired immunity in atherogenesis. Nat. Med. 8 11 (2002) 1218-1226
20. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity [see comments]. N. Engl. J. Med. 320 14 (1989) 915-924
21. Witztum J.L. The oxidation hypothesis of atherosclerosis [see comments]. Lancet 344 8925 (1994) 793-795
22. 2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 14 10 (2008) 1059-1066
23. Berliner J.A., Territo M.C., Sevanian A., Ramin S., Kim J.A., Bamshad B., Esterson M., and Fogelman A.M. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest. 85 4 (1990) 1260-1266
24. Frostegard J., Haegerstrand A., Gidlund M., and Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 90 2-3 (1991) 119-126
25. Frostegard J., Nilsson J., Haegerstrand A., Hamsten A., Wigzell H., and Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc. Natl. Acad. Sci. U. S. A. 87 3 (1990) 904-908
26. Frostegard J., Wu R., Giscombe R., Holm G., Lefvert A.K., and Nilsson J. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler. Thromb. 12 4 (1992) 461-467
27. Quinn M.T., Parthasarathy S., and Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 85 8 (1988) 2805-2809
28. Huang Y.H., Schafer-Elinder L., Wu R., Claesson H.E., and Frostegard J. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin. Exp. Immunol. 116 2 (1999) 326-331
29. Frostegard J., Huang Y.H., Ronnelid J., and Schafer-Elinder L. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler. Thromb. Vasc. Biol. 17 5 (1997) 963-968
30. Chang D.H., Deng H., Matthews P., Krasovsky J., Ragupathi G., Spisek R., Mazumder A., Vesole D.H., Jagannath S., and Dhodapkar M.V. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood 112 4 (2008) 1308-1316
31. Parks B.W., Lusis A.J., and Kabarowski J.H. Loss of the lysophosphatidylcholine effector, G2A, ameliorates aortic atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 26 12 (2006) 2703-2709
32. Kabarowski J.H., Xu Y., and Witte O.N. Lysophosphatidylcholine as a ligand for immunoregulation. Biochem. Pharmacol. 64 2 (2002) 161-167
33. Stemme S., Faber B., Holm J., Wiklund O., Witztum J.L., and Hansson G.K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 92 9 (1995) 3893-3897
34. Heery J.M., Kozak M., Stafforini D.M., Jones D.A., Zimmerman G.A., McIntyre T.M., and Prescott S.M. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J. Clin. Invest. 96 5 (1995) 2322-2330
35. Subbanagounder G., Leitinger N., Shih P.T., Faull K.F., and Berliner J.A. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis : in vitro and in vivo inhibition by WEB 2086. Circ. Res. 85 4 (1999) 311-318
36. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun. Rev. 1 4 (2002) 233-237
37. Shoenfeld Y., Wu R., Dearing L.D., and Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?. Circulation 110 17 (2004) 2552-2558
38. Salonen J.T., Ylä-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssönen K., Palinski W., and Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 (1992) 883-887
39. Lopes-Virella M.F., Virella G., Orchard T.J., Koskinen S., Evans R.W., Becker D.J., and Forrest K.Y. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin. Immunol. 90 2 (1999) 165-172
40. Wu R., de Faire U., Lemne C., Witztum J.L., and Frostegard J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33 1 (1999) 53-59
41. Hulthe J., Wiklund O., Hurt-Camejo E., and Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler. Thromb. Vasc. Biol. 21 2 (2001) 269-274
42. Karvonen J., Paivansalo M., Kesaniemi Y.A., and Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108 17 (2003) 2107-2112
43. Lopes-Virella M.F., Griffith R.L., Shunk K.A., and Virella G.T. En hanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler. Thromb. 11 5 (1991) 1356-1367
44. Shaw P.X., Horkko S., Chang M.K., Curtiss L.K., Palinski W., Silverman G.J., and Witztum J.L. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105 12 (2000) 1731-1740
45. Horkko S., Bird D.A., Miller E., Itabe H., Leitinger N., Subbanagounder G., Berliner J.A., Friedman P., Dennis E.A., Curtiss L.K., Palinski W., and Witztum J.L. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103 1 (1999) 117-128
46. Ameli S., Hultgardh-Nilsson A., Regnstrom J., Calara F., Yano J., Cercek B., Shah P.K., and Nilsson J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16 8 (1996) 1074-1079
47. Freigang S., Horkko S., Miller E., Witztum J.L., and Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18 12 (1998) 1972-1982
48. Palinski W., Miller E., and Witztum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 92 3 (1995) 821-825
49. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., Shaw P.X., Palinski W., Witztum J.L., and Silverman G.J. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9 6 (2003) 736-743
50. Caligiuri G., Khallou-Laschet J., Vandaele M., Gaston A.T., Delignat S., Mandet C., Kohler H.V., Kaveri S.V., and Nicoletti A. Phosphorylcholine-targeting immunization reduces atherosclerosis. J. Am. Coll. Cardiol. 50 6 (2007) 540-546
51. Faria-Neto J.R., Chyu K.Y., Li X., Dimayuga P.C., Ferreira C., Yano J., Cercek B., and Shah P.K. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 189 1 (2006) 83-90
52. Cullen P., Baetta R., Bellosta S., Bernini F., Chinetti G., Cignarella A., Von Eckardstein A., Exley A., Goddard M., Hofker M., Hurt-Camejo E., Kanters E., Kovanen P., Lorkowski S., McPheat W., Pentikainen M., Rauterberg J., Ritchie A., Staels B., Weitkamp B., and De Winther M. Rupture of the atherosclerotic plaque: does a good animal model exist?. Arterioscler. Thromb. Vasc. Biol. 23 4 (2003) 535-542
53. Su J., Georgiades A., Wu R., Thulin T., de Faire U., and Frostegard J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188 1 (2006) 160-166
54. Berglund G., Elmstahl S., Janzon L., and Larsson S.A. The Malmo Diet and Cancer Study. Design and feasibility. J. Intern. Med. 233 1 (1993) 45-51
55. 2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler. Thromb. Vasc. Biol. 27 6 (2007) 1411-1416
56. Sjoberg B.G., Su J., Dahlbom I., Gronlund H., Wikstrom M., Hedblad B., Berglund G., de Faire U., and Frostegard J. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis 203 2 (2009) 528-532
57. Gronlund H., Hallmans G., Jansson J.H., Boman K., Wikstrom M., de Faire U., and Frostegard J. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur. J. Cardiovasc. Prev. Rehabil. 16 3 (2009) 382-386
58. U. de Faire, J. Su, X. Hua, A. Frostegard, M. Halldin, M.L. Hellenius, M. Wikstrom, I. Dahlbom, H. Gronlund, J. Frostegard, Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J. Autoimmun. (2009) [Aug 31, Electronic publication ahead of print].
59. Carrero J.J., Hua X., Stenvinkel P., Qureshi A.R., Heimburger O., Barany P., Lindholm B., and Frostegard J. Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. Nephrol. Dial. Transplant. (2009)
60. Su J., Hua X., Concha H., Svenungsson E., Cederholm A., and Frostegard J. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford) 47 8 (2008) 1144-1150
61. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger Jr. T.A., Jansen-McWilliams L., D'Agostino R.B., and Kuller L.H. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145 5 (1997) 408-415
62. Svenungsson E., Jensen-Urstad K., Heimburger M., Silveira A., Hamsten A., de Faire U., Witztum J.L., and Frostegard J. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104 16 (2001) 1887-1893
63. Asanuma Y., Oeser A., Shintani A.K., Turner E., Olsen N., Fazio S., Linton M.F., Raggi P., and Stein C.M. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349 25 (2003) 2407-2415
64. Roman M.J., Salmon J.E., Sobel R., Lockshin M.D., Sammaritano L., Schwartz J.E., and Devereux R.B. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am. J. Cardiol. 87 5 (2001) 663-666 A611
65. Manzi S., Selzer F., Sutton-Tyrrell K., Fitzgerald S.G., Rairie J.E., Tracy R.P., and Kuller L.H. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42 1 (1999) 51-60
66. Petri M., Roubenoff R., Dallal G.E., Nadeau M.R., Selhub J., and Rosenberg I.H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348 9035 (1996) 1120-1124
67. Svenungsson E., Fei G.Z., Jensen-Urstad K., de Faire U., Hamsten A., and Frostegard J. TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 12 6 (2003) 454-461
68. Su J., Georgiades A., Wu R., Thulin T., de Faire U., and Frostegard J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188 1 (2006) 160-166
69. Frostegard J., Svenungsson E., Wu R., Gunnarsson I., Lundberg I.E., Klareskog L., Horkko S., and Witztum J.L. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 52 1 (2005) 192-200
70. Cederholm A., and Frostegard J. Annexin A5 in cardiovascular disease and systemic lupus erythematosus. Immunobiology 210 10 (2005) 761-768
71. Cederholm A., Svenungsson E., Jensen-Urstad K., Trollmo C., Ulfgren A.K., Swedenborg J., Fei G.Z., and Frostegard J. Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler. Thromb. Vasc. Biol. 25 1 (2005) 198-203
72. Frostegard J., Tao W., Georgiades A., Rastam L., Lindblad U., and Lindeberg S. Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. Nutr. Metab. (Lond) 4 1 (2007) 7
73. Lindeberg S., Berntorp E., Nilsson-Ehle P., Terent A., and Vessby B. Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava study. Am. J. Clin. Nutr. 66 4 (1997) 845-852
74. Lindeberg S., Eliasson M., Lindahl B., and Ahren B. Low serum insulin in traditional Pacific Islanders-the Kitava study. Metabolism 48 10 (1999) 1216-1219
75. Lindeberg S., Soderberg S., Ahren B., and Olsson T. Large differences in serum leptin levels between nonwesternized and westernized populations: the Kitava study. J. Intern. Med. 249 6 (2001) 553-558
76. Su J., Georgiades A., Wu R., Thulin T., de Faire U., and Frostegard J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis (2005)
77. Harnett W., and Harnett M.M. Phosphorylcholine: friend or foe of the immune system?. Immunol. Today 20 3 (1999) 125-129
78. Bochkov V.N., Kadl A., Huber J., Gruber F., Binder B.R., and Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 419 6902 (2002) 77-81
79. Goodridge H.S., Stepek G., Harnett W., and Harnett M.M. Signalling mechanisms underlying subversion of the immune response by the filarial nematode secreted product ES-62. Immunology 115 3 (2005) 296-304
80. Kaveri S.V., Halpern R., Kang C.Y., and Kohler H. Antibodies of different specificities are self-binding: implication for antibody diversity. Mol. Immunol. 28 7 (1991) 773-778
81. Kohler H., Kaveri S., Kieber-Emmons T., Morrow W.J., Muller S., and Raychaudhuri S. Idiotypic networks and nature of molecular mimicry: an overview. Methods Enzymol. 178 (1989) 3-35
82. Kevau I.H. Clinical documentation of twenty cases of acute myocardial infarction in Papua New Guineans. P. N. G. Med. J. 33 4 (1990) 275-280
83. Patel M.S. Diabetes, the emerging problem in Papua New Guinea. P. N. G. Med. J. 27 1 (1984) 1-3
84. Lindeberg S. Stroke in Papua New Guinea. Lancet Neurol. 2 5 (2003) 273 discussion 273
85. Dieterich W., and Schuppan D. Is gliadin harmful from the first morsel?. Dig. Liver. Dis. 39 10 (2007) 917-921
86. Elli L., Dolfini E., and Bardella M.T. Gliadin cytotoxicity and in vitro cell cultures. Toxicol. Lett. 146 1 (2003) 1-8
87. Elkan A.C., Sjoberg B., Kolsrud B., Ringertz B., Hafstrom I., and Frostegard J. Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study. Arthritis Res. Ther. 10 2 (2008) R34
88. Winyard P.G., Tatzber F., Esterbauer H., Kus M.L., Blake D.R., and Morris C.J. Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann. Rheum. Dis. 52 9 (1993) 677-680
89. Kim S.H., Lee C.K., Lee E.Y., Park S.Y., Cho Y.S., Yoo B., and Moon H.B. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol. Int. 24 4 (2004) 230-233